A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia.
Vivash L, Malpas CB, Meletis C, Gollant M, Eratne D, Li QX, McDonald S, O'Brien WT, Brodtmann A, Darby D, Kyndt C, Walterfang M, Hovens CM, Velakoulis D, O'Brien TJ.
Vivash L, et al. Among authors: darby d.
Alzheimers Dement (N Y). 2022 May 5;8(1):e12299. doi: 10.1002/trc2.12299. eCollection 2022.
Alzheimers Dement (N Y). 2022.
PMID: 35574563
Free PMC article.